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Lactose intolerance is a frequent gastrointestinal disease affecting 47% of the Eastern Euro-
pean population. Small intestinal bacterial overgrowth (SIBO) leads to carbohydrate malab-
sorption and therefore to false results during lactose breath and tolerance tests.
Objectives
We aimed to assess the prevalence of lactose maldigestion and intolerance in Hungary and
to investigate the role of combined diagnostic method and testing for SIBO in reducing false
results.
Methods
We retrospectively analyzed data from 264 adult symptomatic patients who underwent 50g
lactose breath and tolerance tests in parallel over a one-year period at our center. A
�20 ppm elevation of H2 or less than 1.1 mmol/l rise of blood glucose was diagnostic for lac-
tose maldigestion. Patients with maldigestion who had symptoms during the test were
defined as lactose intolerant. Patients with an early (�90 min) significant (�20 ppm) rise of
H2 during lactose and/or lactulose breath tests were determined to have SIBO. Patients with
slow/rapid oro-cecal transit and inappropriate preparation before the test were excluded.
Results
49.6% of the 264 patients had lactose maldigestion, and 29.5% had lactose intolerance.
The most frequent symptom was bloating (22.7%), while 34.8% of the study population and
60% of the symptomatic patients had SIBO. In 9.1% and 9.8% of the patients, the lactose
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breath and tolerance test alone gave false positive result compared with the combined
method. SIBO was present in 75% of the false positives diagnosed with breath test only.
Conclusions
The prevalence of lactose intolerance is lower in Hungary compared to the Eastern Euro-
pean value (29.5% vs 47%), so it is worth performing a population-based prospective analy-
sis in this area. A combination of lactose breath and tolerance tests and the careful
monitoring of results (with early H2 rise, lactulose breath test, etc.) can decrease the false
cases caused by e.g. SIBO.
Introduction
Lactose intolerance (LI) is a clinical syndrome characterized by abdominal symptoms after
ingestion of lactose-containing products caused by lactose maldigestion (LM) [1–3]. The most
common cause of primary LM is adult-type hypolactasia [4, 5]. Acquired organic disorders
(e.g. small intestinal bacterial overgrowth (SIBO), celiac disease, inflammatory bowel disease
(IBD), and infectious enteritis (e.g. giardiasis)), can lead to both downregulation of lactase
expression and reduction of absorptive capacity and therefore to secondary lactose malabsorp-
tion [4, 5]. Approximately 47% of the Eastern European population is affected; however, LI is
more common in Asia, Africa, and South America. It affects males and females equally [2, 6].
The prevalence of LM increases with age, however, the LI symptoms decrease in elderly [7, 8].
Because of insufficient lactase activity, lactose can reach the large intestine, where it is fer-
mented by colonic bacteria, gases (H2, CO2, and CH4), short-chain fatty acids, and other prod-
ucts that are formed there. Excessive gas production causes luminal distension and leads to
different gastrointestinal symptoms. The most common complaints are abdominal pain and
discomfort, bloating, flatulence, and diarrhea as with SIBO [1, 3, 9–11]. The diagnostic meth-
ods available for LM or LI are based on the lactose breath test (LBT), lactose tolerance test
(LTT), genetic test, and assessment of lactase activity in jejunal biopsy specimens, the LBT and
LTT being the most popular methods [4]. However, in most studies and at most centers, only
one of the last two methods (LBT or LTT) is used, resulting in higher rates of incorrect diagno-
sis caused by SIBO, for example, which can lead to carbohydrate malabsorption and therefore
to false positive results during the LBT and LTT. Moreover, in some patients with methano-
genic microbiota (e.g. Methanobrevibacter smithii), the bacteria convert hydrogen to methane,
leading to false negative LBT results [2]. Restricting lactose intake or replacing the lactase
enzyme can alleviate unpleasant lactose-induced symptoms [2–5].
SIBO is a condition in which the small intestine is excessively colonized by aerobic and
anaerobic bacteria. Normally, there are fewer than 105 bacteria per milliliter in the duodenal
and jejunal part of the small intestine, with ileal counts reaching 108 per milliliter [12]. The
prevalence of SIBO is unclear, depending on the population and the diagnostic test used. It is
more frequent among the elderly due to reduced gastric acid secretion and medications caus-
ing hypomotility [13]. Disorders disturbing mucosal defense mechanisms can predispose one
to SIBO, intestinal motility disorders and chronic pancreatitis being the most common causes
[14–16]. Other etiological factors are motility disorders (diabetes mellitus, irritable bowel syn-
drome [IBS], use of narcotics, intestinal pseudo-obstruction, etc.), anatomic disorders (adhe-
sions, strictures, diverticulosis, etc.), immunological disorders (e.g. HIV), and metabolic and
systemic diseases (e.g. cirrhosis) [12, 17–19]. SIBO causes mucosal damage and altered motility
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and therefore leads to complex malabsorption (of carbohydrate, fatty acids, proteins, and vita-
mins), diarrhea, bloating, flatulence, and abdominal discomfort [13, 20–23]. A diagnosis of
this disease can be based on carbohydrate breath tests or on an assessment of bacterial concen-
tration from the jejunal aspirate. Although jejunal aspirate culture is the gold standard method,
it is not widely used due to its invasiveness, poor reproducibility, possible contamination, and
patchy disease localization. Carbohydrate breath tests are simple, non-invasive, inexpensive,
and therefore widely used [24–26]. The treatment comprises correction of the underlying
cause, antibiotic therapy, and nutritional support (e.g. lactose-free diet, vitamin replacement,
and correction of nutrient deficiencies). Rifaximine is effective in 80% of patients [27, 28].
Higher doses (1200 or 1600 mg/day) are more effective compared to standard ones (600 or 800
mg/day) [29]. The length of antibiotic therapy is not clearly defined. A single 7–10-day course
can alleviate symptoms in most patients [30]. Repeated or continuous antibiotic therapy
should be useful if symptoms recur [13]. The effectiveness of probiotics is inconclusive, and
generally, they are not recommended in SIBO [18, 31].
In this single-center retrospective study, we aimed to assess the prevalence of LM and LI in
southwest Hungary (Baranya County, except for the Mohács district, with a population of
317,000 people), to investigate the role of a combined diagnostic method (LBT and LTT) in
improving diagnostic accuracy, and to show that parallel testing for SIBO could reduce false
positive cases determined by LBT and/or LTT.
Materials and methods
The key points of the STROBE (Strengthening the Reporting of Observational Studies in Epi-
demiology) guideline [32] were followed in planning and reporting this study (S1 File). We
retrospectively analyzed data from adult symptomatic patients who underwent the LBT and
LTT in parallel at our center (Division of Gastroenterology, First Department of Medicine,
University of Pécs) between 15 February 2016 and 14 February 2017. The LBT and LTT were
carried out with 50g lactose (equal to the content of 1 liter of milk), H2 levels were measured
with Micro H2 instrument (Micro Medical Limited, P.O. Box 6. Rochester, Kent ME1 2AZ
ENGLAND). Before lactose ingestion, baseline end-alveolar H2 and blood glucose levels were
measured (0 min). Then patients drank the set amount of lactose dissolved in 250 ml water.
After this process, end-alveolar H2 and blood glucose levels were measured every 30 minutes
over a three-hour period (in the case of glucose over a two-hour period). Depending on the
clinical situation and patients’ compliance, in clinically uncertain (but not in all) cases, a lactu-
lose breath test with 10g lactulose was carried out to prove or reject the diagnosis of SIBO or
slow oro-cecal transit [26]. A significant,�20 ppm elevation of H2 level during the LBT and/or
less than 1.1 mmol/l rise of blood glucose during the LTT was diagnostic for LM. Patients with
negative LBT and LTT are lactose digesters. Patients with LM who had symptoms during the
test were defined as lactose intolerant. Patients with an early (�90 min) significant (�20 ppm)
rise of H2 during the LBT and/or lactulose breath test were determined to have SIBO [26]. The
diagnostic criteria of the different conditions are summarized in Table 1. For optimal prepara-
tion, patients stopped taking laxatives, antibiotics, and prokinetics, avoided high fiber-contain-
ing foods and fasted for 12 hours, avoided smoking and exercise for at least two hours before
the test. Antiseptic mouthwash was not given routinely, only for those with high initial H2
value (>20 ppm). We excluded patients with inappropriate preparation for the test (baseline
H2 level>20 ppm) and those with suspected rapid or slow oro-cecal transit (clinical symptoms
of gastroparesis and a negative LBT with a positive LTT or no significant rise of H2 during a
180-min lactulose breath test compared to the baseline value). We collected data on the base-
line characteristics of the analyzed population (mean age, gender differences, and their
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correlation with the outcome measures), the diagnostic tests (baseline and maximum H2 and
glucose levels, time of glucose and H2 peak, and the presence of LM), the presence and type of
symptoms occurring during the test (abdominal pain, cramps, discomfort, bloating, diarrhea,
nausea/vomiting, borborygmi, and other gastrointestinal symptoms, such as increased bowel
motility, flatulence, belching, a sensation of fullness in the stomach, a burning sensation in the
stomach, an increased sensation for defecation or headache [3, 33]), and the presence of LI
and SIBO. The data collection and research were approved by the director of the Clinical Cen-
ter and the director of the First Department of Medicine of the University of Pécs (Institutional
Review Board), and the study process was carried out in accordance current laws and regula-
tions (Case Number: PTE/98494/2018). All patient data were fully anonymized after the spe-
cific parameters necessary for our research were collected. However, our analysis was made
retrospectively; therefore, we have not included patients’ data who had refused scientific pur-
pose data handling.
Statistical analysis
Data were analyzed using SPSS 25.0 software. Means, standard deviation, minimum and maxi-
mum values, and relative frequency were calculated for descriptive statistics. The Pearson cor-
relation, the Mann–Whitney test, and odds ratios (OR) with 95% confidence interval (CI)
were used for other analyses. A p-value of less than 0.05 was accepted as statistically
significant.
Results
A total of 310 patients were assessed in the period noted above. Twenty-four of them were
excluded because of inappropriate preparation and 22 (7.6% of the well-prepared patients)
were ruled out because of slow oro-cecal transit, leaving 264 patients, 185 females (F: 70.1%),
and 79 males (M: 29.9%), for statistical analysis. No patient had rapid transit in our study
group. The mean age of the analyzed study group was 40.3 years (F: 40.6 years; M: 39.5 years).
Based on the LBT and/or LTT results, 49.6% (131/264) of the study population had LM
(LBT and/or LTT positivity), as represented in Fig 1. Seventy-eight (78/131, 59.5%) of them
had symptoms after lactose ingestion and were therefore defined as lactose intolerant (78/264,
29.5%, Fig 1). Combined positivity (LBT+LTT) was found in 30.7% (81/264) of the patients
(see Fig 1). There was no significant difference between females and males in the prevalence of
normal lactose digestion, LM, and LI (p> 0.05). There was no significant correlation between
Table 1. The summary of the different diagnostic criteria used in our study.
Lactose maldigester (LM) LBT:�20 ppm elevation of H2 compared to baseline level
and/or
LTT: <1.1 mmol/l rise of blood glucose level compared to baseline value
Normal lactose digestion Negative LBT (<20 ppm elevation of H2 level)
and
Negative LTT (�1.1 mmol/l elevation of blood glucose)
Lactose intolerance (LI) Lactose maldigesters, who had symptoms during the test period
Small intestinal bacterial
overgrowth (SIBO)
Significant (�20 ppm) rise of H2 during lactose and/or lactulose breath test,
within 90 minutes
Slow oro-cecal transit (excluded) Clinical symptoms of gastroparesis and a negative LBT with a positive LTT or
no significant rise of H2 during a 180-min lactulose breath test compared to
the baseline value
LBT: lactose breath test; LTT: lactose tolerance test.
https://doi.org/10.1371/journal.pone.0230784.t001
PLOS ONE Lactose intolerance and the role of small intestinal bacterial overgrowth
PLOS ONE | https://doi.org/10.1371/journal.pone.0230784 May 8, 2020 4 / 13
age and digester (p = 0.352), maldigester (p = 0.352), and LI (p = 0.098) status. The basic results
of the analyzed population are summarized in Fig 1. The gender-related results are represented
in S1 Fig.
Lactose maldigestion and intolerance based on the LBT
Based on the LBT only, 39.8% of the tested study population (105/264) were LM, and 73 of
them (69.5%) had symptoms during the test; therefore, 27.7% (73/264) of the population was
defined as lactose intolerant (see Fig 2). The majority (159/264, 60.2%) of the patients had a
negative LBT, however; 13.8% (22/159) of them had symptoms after lactose ingestion, mean-
ing that 8.3% (22/264) of the analyzed patients had symptoms without a positive test result, as
represented in Fig 2. There was a weak negative correlation between age and baseline H2
(p = 0.009; r = -0.161). There was no significant connection between gender, age, and LBT pos-
itivity (gender: p> 0.05; age: p = 0.792). The results are summarized in Fig 2.
Lactose maldigestion and intolerance based on the LTT
Based on an analysis of the LTT alone measured in parallel, 40.5% of the same study popula-
tion (107/264) were maldigesters and 65 of them (60.7%) had symptoms during the test.
Therefore, 24.6% (65/264) of the population was defined as lactose intolerant (see Fig 2). The
majority (157/264, 59.5%) of the patients had a negative LTT; however, 19.1% (30/157) of
them had symptoms after lactose ingestion, meaning that 11.4% (30/264) of the analyzed
patients had symptoms without a positive test result (Fig 2). Men had a significantly higher
Fig 1. Summary of the basic results in the analyzed study population. A significant,�20 ppm elevation of H2 level during LBT
and/or less than 1.1 mmol/l rise of blood glucose during LTT were diagnostic for lactose maldigestion. Patients with negative LBT
and LTT are lactose digesters. Patients with LM who had symptoms during the test were defined as lactose intolerant. Patients with an
early (�90 min) significant (�20 ppm) rise of H2 during LBT and/or lactulose breath test were defined to have SIBO. LBT: lactose
breath test; LTT: lactose tolerance test; SIBO: small intestinal bacterial overgrowth.
https://doi.org/10.1371/journal.pone.0230784.g001
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baseline (p< 0.001) and maximum (p = 0.015) glucose level. There was a moderate positive
correlation between age and glucose levels (baseline: p< 0.001; r = 0.338; maximum:
p< 0.001; r = 0.222). There was no significant connection between gender, age, and LTT posi-
tivity (gender: p> 0.05; age: p = 0.378). The results are summarized in Fig 2.
Combined LHBT and LTT positivity
Combined positivity (LBT+LTT) was found in 30.7% (81/264) of the patients, 74% of them
(60/81) had symptoms. Therefore, 22.7% (60/264) of the study population was lactose intoler-
ant based on the combined results (see Fig 2). In the majority (183/264, 69.3%) of the popula-
tion one or both tests were negative; however, 19.1% (35/183) of them had symptoms meaning
that 13.3% (35/264) of the analyzed patients had symptoms without combined test positivity
(Fig 2). The results are summarized in Fig 2.
Clinical symptoms
Thirty-six percent (95/264) of the patients had symptoms after lactose ingestion (see Fig 1),
bloating being the most frequent (60/264; 22.7%), as seen in Fig 3. There was no statistically
significant difference between females and males in the presence of symptoms (p> 0.05).
Those who had nausea/vomiting were significantly older (p = 0.014). Otherwise, there was no
statistically significant correlation between age and symptoms (p = 0.204). 12.8% (17/133) of
the lactose digester patients (the LBT and LTT are negative) and 59.5% (78/131) of the maldi-
gester patients (at least one of the tests is positive) had clinical symptoms (see Fig 4). Based on
the latest meta-analysis conducted by our workgroup [34], we hypothesize that IBS may be a
contributing factor in LI among lactose maldigesters. Figs 3 and 4 show the frequency of the
different symptoms in the study population, and among lactose maldigesters/digesters and
Fig 2. Summary of the results based separately on the LBT, LTT, and on the combination of them. LBT: lactose breath test; LTT: lactose
tolerance test.
https://doi.org/10.1371/journal.pone.0230784.g002
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lactose intolerant/tolerant patients. Female/male data regarding symptoms are represented in
S2 Fig.
The role of SIBO
Approximately one-third (92/264; 34.8%) of the study population (see Fig 1) and 60% (57/95)
of the symptomatic patients had SIBO based on the definition (see Table 1). There was no sig-
nificant difference in the presence of SIBO between females and males (F: 68/185, 36.8%; M:
24/79, 30.4%, p> 0.05); furthermore, there was no significant correlation between age and
SIBO (p = 0.848). SIBO patients had significantly higher maximum H2 levels (p< 0.001), and
they reached the H2 peak later (p< 0.001). Moreover, they had lower maximum glucose levels
(p< 0.001), and LTT positivity was significantly more frequent in this patient group (OR =
5.833; 95% CI: 3.356–10.138). Symptoms were more common in SIBO patients compared to
non-SIBO patients (OR = 5.743; 95% CI: 3.300–9.994), especially abdominal discomfort (OR =
3.201; 95% CI: 1.196–8.565), bloating (OR = 4.798; 95% CI: 2.606–8.833), diarrhea (OR =
6.443; 95% CI: 2.737–15.168), and other symptoms (OR = 5.825; 95% CI: 2.193–15.469).
In 90.9% (240/264) of the patients the LBT gave correct diagnosis (30.7% true positive: 81/
264, 60.2% true negative: 159/264) of LM (or the lack of it) using combined LBT and LTT as
reference. False positive results were found in 9.1% (24/264) of the cases; however, there are no
false negatives in this setting (see Fig 5). LBT in this setting has 100% sensitivity, 86.9% speci-
ficity, 77.1% positive predictive value, and 100% negative predictive value. SIBO was found in
76.5% (62/81) of the true positive and in 75% (18/24) of the false positive patients.
In 90.2% (238/264) of the patients the LTT gave correct diagnosis (30.7% true positive: 81/
264, 59.5% true negative: 157/264) of LM (or the lack of it) using combined LBT and LTT as
Fig 3. The frequency and distribution of different symptoms in the entire study population. Other symptoms comprise increased bowel motility,
flatulence, belching, sensation of fullness in the stomach, headache, burning sensation in the stomach, or increased sensation for defecation.
https://doi.org/10.1371/journal.pone.0230784.g003
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Fig 4. The frequency and distribution of different symptoms among lactose digesters/maldigesters, and among lactose tolerant/intolerant patients. A
significant,�20 ppm elevation of H2 level during LBT and/or less than 1.1 mmol/l rise of blood glucose during LTT were diagnostic for lactose maldigestion. Patients
with negative LBT and LTT are lactose digesters. Patients with LM who had symptoms during the test were defined as lactose intolerant. Other symptoms comprise
increased bowel motility, flatulence, belching, sensation of fullness in the stomach, headache, burning sensation in the stomach, or increased sensation for defecation.
https://doi.org/10.1371/journal.pone.0230784.g004
Fig 5. The diagnostic accuracy of the LBT and LTT verified by the combined results of the tests. LBT: lactose breath test; LTT: lactose tolerance test.
https://doi.org/10.1371/journal.pone.0230784.g005
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reference. False positive results were found in 9.8% (26/264) of the cases; however, there are no
false negatives in this setting (see Fig 5). Therefore, LTT has 100% sensitivity, 85.8% specificity,
75.7% positive predictive value, and 100% negative predictive value. SIBO was found in 76.5%
(62/81) of the true positive, but surprisingly in 0% (0/26) of the false positive patients.
Based on these findings the combination of the LBT and LTT and the careful monitoring of
results (with e.g. early H2 rise, parallel performed lactulose breath test) can decrease false
results caused by e.g. SIBO.
Discussion
In this retrospective, single-center study, we analyzed the epidemiological characteristics of LI
in southwest Hungary and assessed the role of combined diagnostic method and small intesti-
nal bacterial overgrowth in the accuracy of the diagnosis.
LI is a relatively common problem in the white population, affecting approximately 47% of
Eastern European adults [2, 6]. There are widely-used, inexpensive, non-invasive, diagnostic
methods based on measurement of end-alveolar H2 concentration (LBT) or blood glucose
(LTT) [2–5]. The sensitivity and specificity of these tests are relatively high, but they depend on
the ingested lactose dose (25g LBT: 82% and 95%; 25g LTT: 78% and 93%; 50g LBT: 92% and
83%; 50g LTT: 94% and 90%) [35, 36]. Other circumstances, such as SIBO, antibiotic usage, lung
diseases, inappropriate preparation, and abnormal gastric emptying can influence their diagnos-
tic accuracy. A combination of these tests and careful evaluation of the results can reduce the
false positive or negative cases; however, in most studies, they are used separately [37].
The gold standard diagnostic method is the testing of lactase activity in duodenal and jeju-
nal biopsy samples taken from the mucosa. However, due to the invasiveness, high costs, and
patchy enzyme expression, it is less frequently performed compared to the tests noted above.
Moreover, it should be considered that similar lactase activity in two patients might result in
different LBT results due to the different activity and composition of the intestinal microbiota.
There are several genes associated with lactase non-persistence (C/T_13910 with CC genotype;
G/A_22018 with GG genotype), but the availability of genetic testing is variable, and its costs
are relatively high. Moreover, the lactase non-persistence allele is not always associated with
LM [2, 3, 5, 34]. A Hungarian study, published by Nagy et al., determined the applicability of
the LBT in comparison with genetic screening (C/T_13910). They found that 37% of the ana-
lyzed population had lactase non-persistence, which correlated well with positive LBT results
is symptomatic children [38]. We found similar LBT positivity among symptomatic adults.
Another retrospective study from Hungary, conducted by Buzás et al., also underlined that
both genetic and breath tests are sufficiently accurate [39].
In this study, we presented epidemiological data on the prevalence of LM and LI in south-
west Hungary, we analyzed the frequency of the most common symptoms, we demonstrated
that combined analysis of LBT and LTT can improve diagnostic accuracy and the parallel test-
ing for SIBO could reduce false cases caused for example by SIBO. It should also be mentioned
that the study population had a very large female representation (185 vs 79); however, there
were no statistically significant gender-related differences regarding LM, LI, LBT/LTT positiv-
ity, symptoms frequency, and prevalence of SIBO, which underlines the literature data in case
of LI [2]. Moreover, despite the literature data [7, 8, 13], we did not find any age-related corre-
lations in the outcomes mentioned above.
The limitations of our results should be considered for a correct interpretation, thus possi-
bly influencing outcomes. Firstly, our results are based on a single-center retrospective medical
database analysis. Secondly, we only analyzed the results in a one-year period; therefore, the
number of enrolled patients is relatively low. Thirdly, the amount of ingested lactose can
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influence the prevalence of LM and LI, and the frequency of symptoms. We used a relatively
high dose of lactose and we did not perform blinded testing with placebo. Based on the retro-
spective character, follow-up after antibiotic treatment or low-lactose diet could not be per-
formed to confirm the diagnosis of SIBO and LI based on symptom relief. Moreover, lactulose
breath test was performed only in clinically uncertain cases, not on all patients. Therefore, the
true diagnosis and prevalence of LI and SIBO could not be assessed correctly. Only patients
with high initial end-alveolar H2 concentration got antiseptic mouthwash. Another significant
limitation is that our study group comprises symptomatic patients referred to our clinic, thus
potentially leading to sampling bias. It also should be considered that we did not measure
methane levels in the end-alveolar gas samples to determine false negative LBT caused by
methane producing bacteria. Based on the recent results [40] false negative LBT (5–15%) are
mainly caused by methane production. Finally, the symptoms of the patients are subjective,
thus possibly prompting inaccurate conclusions. Interpretation of patient-reported symptoms
will differ between clinicians; therefore, standardized symptom definitions should have been
used to minimize errors. According to the Oxford Centre for Evidence-Based Medicine 2011,
the evidence level of our findings is level 3 [41].
Conclusions
Based on our results, we can conclude that the prevalence of LI is lower in Hungary compared
to the Eastern European value (29.5% vs 47%) and that it is worth performing a population-
based prospective analysis in this area. During the provocation tests, 59.5% of lactose maldige-
sters had IBS-like symptoms (lactose intolerance), but the role of IBS in the background is
unknown. SIBO was relatively common among symptomatic patients (60%), and this may
influence the diagnostic accuracy of lactose maldigestion, based on the LBT and LTT as the
only diagnostic test. Therefore, a combination of the LBT and LTT and careful monitoring of
results may decrease the false cases caused by e.g. SIBO.
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